In this issue
Hereditary angioedema (HAE) attacks can be debilitating and potentially life-threatening, particularly when they affect the abdomen or airways. Recently targeted prophylactic medications have been developed and licensed and treatment practices have evolved. Long-term prophylaxis (LTP) is recommended in international guidelines to reduce attack frequency and improve quality of life (QoL) for patients.
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles

We’ve noticed you’re accessing
from North/South America.
from North/South America.